Cigna Investments Inc. New Sells 29 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Cigna Investments Inc. New cut its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.7% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 3,930 shares of the medical research company’s stock after selling 29 shares during the quarter. Cigna Investments Inc. New’s holdings in Thermo Fisher Scientific were worth $2,431,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Mission Wealth Management LP raised its position in Thermo Fisher Scientific by 8.6% during the first quarter. Mission Wealth Management LP now owns 4,326 shares of the medical research company’s stock worth $2,514,000 after acquiring an additional 342 shares in the last quarter. Avior Wealth Management LLC increased its position in Thermo Fisher Scientific by 7.9% during the first quarter. Avior Wealth Management LLC now owns 4,251 shares of the medical research company’s stock worth $2,471,000 after buying an additional 313 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Thermo Fisher Scientific by 2.1% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 86,668 shares of the medical research company’s stock valued at $49,366,000 after buying an additional 1,754 shares during the last quarter. 1834 Investment Advisors Co. increased its holdings in shares of Thermo Fisher Scientific by 10.0% during the 1st quarter. 1834 Investment Advisors Co. now owns 1,809 shares of the medical research company’s stock worth $1,051,000 after acquiring an additional 164 shares during the last quarter. Finally, Connecticut Wealth Management LLC lifted its holdings in Thermo Fisher Scientific by 1.1% during the 1st quarter. Connecticut Wealth Management LLC now owns 4,842 shares of the medical research company’s stock valued at $2,814,000 after purchasing an additional 54 shares during the last quarter. Institutional investors own 89.23% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the company. Raymond James upped their target price on Thermo Fisher Scientific from $650.00 to $660.00 and gave the company an “outperform” rating in a research report on Thursday, July 25th. Bernstein Bank upped their price target on shares of Thermo Fisher Scientific from $565.00 to $625.00 and gave the company a “market perform” rating in a research note on Tuesday, October 22nd. Morgan Stanley raised their target price on shares of Thermo Fisher Scientific from $655.00 to $680.00 and gave the stock an “overweight” rating in a report on Friday, September 20th. Royal Bank of Canada cut their price target on Thermo Fisher Scientific from $767.00 to $718.00 and set an “outperform” rating for the company in a research note on Thursday, October 24th. Finally, Robert W. Baird dropped their price objective on Thermo Fisher Scientific from $632.00 to $622.00 and set an “outperform” rating for the company in a report on Thursday, October 24th. Four investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $649.33.

Thermo Fisher Scientific Trading Down 0.7 %

NYSE TMO opened at $546.55 on Friday. The company has a current ratio of 1.63, a quick ratio of 1.26 and a debt-to-equity ratio of 0.64. The firm has a market capitalization of $208.78 billion, a P/E ratio of 34.27, a PEG ratio of 3.64 and a beta of 0.77. The business has a fifty day simple moving average of $600.36 and a 200 day simple moving average of $583.31. Thermo Fisher Scientific Inc. has a 12 month low of $433.15 and a 12 month high of $627.88.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, October 23rd. The medical research company reported $5.28 EPS for the quarter, topping the consensus estimate of $5.25 by $0.03. The firm had revenue of $10.60 billion for the quarter, compared to analysts’ expectations of $10.63 billion. Thermo Fisher Scientific had a net margin of 14.48% and a return on equity of 17.49%. The company’s quarterly revenue was up .2% compared to the same quarter last year. During the same quarter last year, the firm earned $5.69 EPS. On average, analysts predict that Thermo Fisher Scientific Inc. will post 21.68 EPS for the current fiscal year.

Insider Buying and Selling

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction dated Friday, October 25th. The shares were sold at an average price of $560.16, for a total value of $168,048.00. Following the sale, the executive vice president now owns 16,663 shares of the company’s stock, valued at approximately $9,333,946.08. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction on Monday, October 28th. The stock was sold at an average price of $554.29, for a total transaction of $5,542,900.00. Following the transaction, the chief executive officer now owns 121,192 shares of the company’s stock, valued at $67,175,513.68. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Gianluca Pettiti sold 300 shares of the stock in a transaction dated Friday, October 25th. The stock was sold at an average price of $560.16, for a total transaction of $168,048.00. Following the transaction, the executive vice president now owns 16,663 shares of the company’s stock, valued at $9,333,946.08. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 12,300 shares of company stock valued at $6,831,268. 0.34% of the stock is owned by insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.